SI-BONE Q1 Revenue Tops Estimates, Reaching $52.59 Million
SIBN is trading near its 52-week low of $11.48 (9.3% above the low) on elevated volume (2.6× avg).
Summary
SI-BONE, Inc. reported first-quarter revenue of $52.588 million, significantly exceeding the IBES estimate of $51.1 million. The company also achieved a strong gross margin of 79.8%, though it posted a net loss of $4.334 million for the quarter. This revenue beat indicates robust demand for SI-BONE's medical devices and continues the positive growth trajectory seen in its 2025 annual report, which highlighted a 20.2% revenue increase. The better-than-expected top-line performance is a material positive for the stock, suggesting operational strength. Traders will now focus on the company's path to profitability and any updated guidance for the remainder of the year.
At the time of this announcement, SIBN was trading at $12.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $513.7M. The 52-week trading range was $11.48 to $21.89. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.